Uncategorized
Bevacizumab monotherapy shows potential for some patients with ROP
Bevacizumab (Avastin, Genentech) monotherapy for zone I retinopathy of prematurity (ROP) might have
potential for treating pre-term infants who are in phase II of the pathogenesis of ROP.